TransMedics Group Inc (NAS:TMDX)
$ 145.96 2.885 (2.02%) Market Cap: 4.81 Bil Enterprise Value: 4.97 Bil PE Ratio: 0 PB Ratio: 30.07 GF Score: 80/100

Transmedics Group Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 17, 2020 / 12:00PM GMT
Release Date Price: $16.48 (-3.68%)
David Ryan Lewis
Morgan Stanley, Research Division - MD

Well, good morning, and welcome to Day 4 of the Morgan Stanley Healthcare Conference 2020. My name is David Lewis, medical device analyst at Morgan Stanley. We appreciate your attendance throughout these last four days. We've got another very exciting day here on Day 4, really focusing on some mid-cap emerging technology companies, and I'm delighted to have with us here to start the day, one of those -- such companies, TransMedics. We've got their CEO, Waleed Hassanein; and Stephen Gordon, their CFO. We're going to dispense with the preamble. We're going to get straight into Q&A.

Questions & Answers

David Ryan Lewis
Morgan Stanley, Research Division - MD

And now, Waleed, it's interesting. Transplantation is a bit of a -- every company has reacted to COVID recovery differently. I think initially, people said, "Hey, transplantation is something that cannot be deferred, but yet these patients are immunocompromised. So COVID has impacted your business in particularly unique ways." Help us

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot